<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> (TZDs), ligands for peroxisome proliferator-activated receptor gamma, are <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents that improve <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> by decreasing <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in <z:mp ids='MP_0001261'>obese</z:mp> diabetic animal models and patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We have studied whether <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, a TZD, can exert a direct effect against pancreatic beta-cell lipoapoptosis </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: MIN6 cells were cultured in medium containing either 5.6 (low <z:chebi fb="105" ids="17234">glucose</z:chebi>) or 25 mM <z:chebi fb="105" ids="17234">glucose</z:chebi> (high <z:chebi fb="105" ids="17234">glucose</z:chebi>) in the presence or absence of 0.5 mM <z:chebi fb="2" ids="29889">palmitate</z:chebi> for 48 h </plain></SENT>
<SENT sid="3" pm="."><plain>We examined the effect of 10 microM <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on MIN6 cells on <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion, cellular ATP, uncoupling protein-2 (UCP-2) <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression, intracellular <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content, reactive oxygen species production, the number of apoptotic cells and nuclear factor-kappaB (NF-kappaB) activity </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> recovered partly impaired <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion and cellular ATP in MIN6 cell exposed to high <z:chebi fb="105" ids="17234">glucose</z:chebi> with 0.5 mM <z:chebi fb="2" ids="29889">palmitate</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> suppressed intracellular <z:chebi fb="0" ids="17855">triglyceride</z:chebi> accumulation in cells exposed to high <z:chebi fb="105" ids="17234">glucose</z:chebi> with 0.5 mM <z:chebi fb="2" ids="29889">palmitate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="2" ids="29889">Palmitate</z:chebi>-induced upregulation of UCP-2 mRNA levels was suppressed by <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in a dose-dependent manner </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> decreased <z:chebi fb="2" ids="29889">palmitate</z:chebi>-induced reactive oxygen species production in MIN6 cells by 24% and in mouse islet cells by 53% </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> also decreased <z:chebi fb="2" ids="29889">palmitate</z:chebi>-induced NF-kappaB activity by 40% and protected beta-cells from <z:chebi fb="2" ids="29889">palmitate</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by 22% in MIN6 cell </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> attenuated fatty acid-induced <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in pancreatic beta-cells </plain></SENT>
<SENT sid="10" pm="."><plain>TZDs might be used as a mean for maintaining beta-cell survival and preserving capacity of insulin secretion in patients with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>